Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00289029 · ClinicalTrials.gov registry record · Phase 4
A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography
A Phase 4 study, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- Phase 4
- Development phase
- 400
- Enrollment target
NCT00289029 is a Phase 4 study that has completed, run by Bracco Diagnostics. The registered enrollment target is 400 participants.
The verdict
NCT00289029, a Phase 4 study, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 400 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with moderate to severe renal insufficiency undergoing cardiac angiography. Serum creatinine will be measured before and up to 48-72 hours after the administration of the contrast agent to evaluate renal function.
Interventions
- DRUG Iopamidol 370 mgI/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2005-07 |
| Est. Completion | 2006-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00289029
The ClinicalTrials.gov registry entry for NCT00289029 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iopamidol 370 mgI/mL is the first listed.
NCT00289029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00289029 about?
NCT00289029 is a clinical study titled "A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography". The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with moderate to severe renal insufficiency undergoing cardiac angiography. Serum creatinine will be measured before and up to 48-72 hours aft...
What is the current status of trial NCT00289029?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 400 participants. The study started on 2005-07. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00289029?
The interventions under investigation include: Iopamidol 370 mgI/mL (DRUG).
Who is sponsoring clinical trial NCT00289029?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.